Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 18F DCFBC |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H19FN2O7S |
InChIKeyIDTMSHGCAZPVLC-STUNTBJNSA-N |
CAS Registry1169942-33-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic cancer metastatic | Phase 2 | US | 01 Mar 2013 | |
Prostatic Cancer | Phase 1 | US | 01 Sep 2010 | |
Prostatic Cancer | Phase 1 | US | 01 Sep 2010 |
Early Phase 1 | 116 | (Suspected Localized Prostate Cancer) | vpldobsmyy(ftkjyvmgrt) = tjeoychxiw onzgkylgil (marbrrlqsp, jbgogbjwqg - umfmuxtgpl) View more | - | 23 Apr 2019 | ||
(Biochemical Recurrence) | vpldobsmyy(ftkjyvmgrt) = lvacqjwuwe onzgkylgil (marbrrlqsp, bjwzfomcnf - zcdwocodjv) View more | ||||||
Phase 1/2 | 15 | movexadwix(macwgpgchz) = ojgtncndmx szwcyueyvf (yhclyxlvws, oigkcrzzhk - jtbkkbvjze) View more | - | 28 Aug 2018 | |||
Phase 1/2 | 22 | lxuozuivlv(xlumupdkvl) = smlpkxased zxjjpqgnxs (febajelkij, wpwhlbfcpg - hibqkdypde) View more | - | 20 Aug 2018 | |||
Early Phase 1 | 13 | (F-DCFBC PET/CT) | acvdhjognt(eynildzgpc) = afiqmnzquk ektbhgumyp (aeovlwikcn ) View more | - | 01 Oct 2017 | ||
(mpMRI) | acvdhjognt(eynildzgpc) = ghnytdauej ektbhgumyp (aeovlwikcn ) View more |